| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 39.87 | 0.04 (+0.10%) | 34.01 - 58.00 | 109.0 thousand |
Market data as of 4:00PM 05/17/13. Quotes are delayed by at least 15 min.
| Open | 39.96 |
|---|---|
| Previous Close | 39.83 |
| Day's Range | 39.79 - 40.37 |
| Market Cap | 1.1B |
| Avg Volume (10 Day) | 119.6K |
| Price/Earnings (Trailing 12 Mo.) | 3.7x |
| Earnings Per Share (Trailing 12 Mo.) | 0.82 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Pass |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Fail |
| Increased shareholder value? | Fail |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Neutral |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Pass |
| Borrows within reasonable limits? | Pass |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Fail |
| Has sufficient liquidity? | Pass |
Synageva BioPharma™ Joins the International MPS Network in Support of MPS Awareness Day 2013
Business Wire - Wednesday 05/15/2013 7:00 AM ET
Synageva BioPharma™ Announces One Year of Treatment Data with Sebelipase Alfa in Late Onset LAL Deficiency
Business Wire - Thursday 05/09/2013 7:01 AM ET
Synageva BioPharma™ Reports First Quarter 2013 Financial Results
Business Wire - Tuesday 05/07/2013 4:05 PM ET
| GEVA | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | 510.16% | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | 0.00 | |
| LT Debt/Equity | 0.00 | |
| Earnings Yield | 27.03% | |
| Price/Sales | 61.51 |
| Company | Last | Change |
|---|---|---|
| 6.75 | -7.66% | |
| Puma Biotechnology Inc | 37.36 | +7.42% |
| ACADIA Pharmaceuticals Inc | 13.27 | +2.00% |
| Nektar Therapeutics | 9.79 | +1.98% |
| Lexicon Pharmaceuticals Inc | 2.21 | +1.38% |
Data is delayed by at least 15 min.